Navigation Links
Presentation at Bio Contact Quebec 2007
Date:10/2/2007

HAE:TSX

MONTREAL, Oct. 2 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company developing high-value human proteins, announces that Mr. Joseph Galli, Chairman and Chief Executive Officer, will be presenting at BioContact Quebec 2007. Mr. Galli will be speaking on Wednesday, October 3, 2007 at 16:30 in the Bellevue Room, Chateau Frontenac in Quebec City.

About BioContact Quebec 2007

BioContact Quebec 2007 (http://www.biocontact.qc.ca) is a biopharmaceutical partnership symposium gathering over 1200 participants. More than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as cancer, cardiology, drug delivery systems, endocrinology, genomics/proteomics, immunology/infectiology, neurobiology, virology and medical technologies.

About Haemacure

Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats.

Haemacure's lead product candidate, Hemaseel(TM)HMN, is a human-derived fibrin sealant in late-stage clinical development. Haemacure's second product candidate is human thrombin, a component of its fibrin sealant. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical hemostats, biomaterial combinations and drug delivery in select therapeutic areas. Haemacure has recently discovered additional specialty proteins in its plasma-derived intermediates and will advance these specialty proteins through partnerships with other pharmaceutical and biotechnology companies.

Forward-looking Statements

Certain statements contained in this news release and oral statements made by representatives of Haemacure that are not historical facts may be considered forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, the ability of Haemacure to set up its planned manufacturing facility, the completion and outcome of clinical studies as well as the development of new products, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure Corporation disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Onchocerciasis: Presentation And Treatment
2. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
3. Implantable Contact Lens Found Safe and Effective
4. Contact Lenses Found To Slow Progression Of Myopia in Kids
5. Reduce eye infection through new-age contact lenses
6. New contact lens materials
7. Newborns Know how to make eye contact
8. Contact Lenses Implicated in Fungal Infections
9. Headway in identification of allergens of contact dermatitis
10. Alarm Raised for Contact Lens Wearers
11. Contact Lens Care Products Results In Eye Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... The Smart Machine ... from Oxford University predict that 47 percent of all jobs in the United States ... “smart” and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now ... . Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic ... Cut Pro X. , With ProGlass Prism users are given the tools and ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... their offering. ... research Dry eye Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are ... are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Feb. 23, 2017 The U.S. Food ... PhenoTest BC Kit, performed on the Pheno System. ... that cause bloodstream infections and provide information about ... to (antibiotic sensitivity). The test also reduces the ... important information, which can guide antibiotic treatment recommendations ...
Breaking Medicine Technology: